chrisvoncsefalvay/vaers-outcomes huggingface dataset:
tiny red spot right where the injection; a tiny bit of itching; little bit of redness where the band aid touched her skin; This is a spontaneous report from a Pfizer-sponsored program from a contactable consumer (pateint). A 70-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number was not reported), via an unspecified route of administration on 25Feb2021 (at the age of 70-year-old) as single dose for covid-19 immunisation. Medical history included breast cancer that spread to lymph nodes diagnosed in 2018, removed whole lobe of lung, double mastectomy and allergic to the glue in band aids. Patient reported that she was a two time cancer survivor. She was diagnosed with breast cancer in 2018 that spread to her lymph nodes.  While getting radiation for that, they found an 11 mm spot of cancer in the lower right lobe of her lung. They removed the whole lobe on an unspecified date. Patient had a double mastectomy on an unspecified date and total of 29 lymph nodes removed through all that. The patient's concomitant medications were not reported. Patient had a little bit of redness where the band aid touched her skin on 25Feb2021. The next day, on 26Feb2021, patient had a tiny red spot right where the injection was. Then the redness was gone and the tiny bit itching started on the same day on 26Feb2021. But the itching only lasted a day or so. Patient reported that typically she use special band aids from home that don't cause her to itch, as she has been told she was allergic to the glue in band aids, but didn't bring her band aids with her when she got the shot.  She came home after getting the shot and took the band aid off. Patient recovered from "a little bit of redness where the band aid touched her skin" and "tiny bit of itching" on an unspecified date, while unknown outcome for tiny red spot right where the injection.    No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Her husband states that it looks reddish; when she touches it, it is sensitive to the touch; She states it is also hard; Feels like some type of fibromyalgia; Inappropriate schedule of vaccine administered; She started to feel a lump in the side and top of her head/she reports she still has the lump/the lump is about the size of a quarter; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (She started to feel a lump in the side and top of her head/she reports she still has the lump/the lump is about the size of a quarter), ERYTHEMA (Her husband states that it looks reddish), HYPERAESTHESIA (when she touches it, it is sensitive to the touch), INDURATION (She states it is also hard) and FIBROMYALGIA (Feels like some type of fibromyalgia) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 017E21A, 031M20A and 042L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included LATANOPROST, AMLODIPINE BESYLATE, FAMOTIDINE (PEPCID AC), MULTIVITAMINS [VITAMINS NOS], MAGNESIUM, CALCIUM, VITAMIN D NOS and RABEPRAZOLE SODIUM (ACIPHEX) for an unknown indication.   On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 18-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 18-Aug-2021, the patient experienced SWELLING (She started to feel a lump in the side and top of her head/she reports she still has the lump/the lump is about the size of a quarter). 18-Aug-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered). On 21-Aug-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced ERYTHEMA (Her husband states that it looks reddish), HYPERAESTHESIA (when she touches it, it is sensitive to the touch), INDURATION (She states it is also hard) and FIBROMYALGIA (Feels like some type of fibromyalgia). On 18-Aug-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) had resolved. At the time of the report, SWELLING (She started to feel a lump in the side and top of her head/she reports she still has the lump/the lump is about the size of a quarter), ERYTHEMA (Her husband states that it looks reddish), HYPERAESTHESIA (when she touches it, it is sensitive to the touch), INDURATION (She states it is also hard) and FIBROMYALGIA (Feels like some type of fibromyalgia) had resolved.            Weight of patient reported 111 without units  Concomitant medications also include ACIDHEX.  No treatment medications were provided.  The patient confirmed the symptom they reported having ended up going away in four day and they are doing fine now.   Most recent FOLLOW-UP information incorporated above includes: On 31-Aug-2021: follow up received- event outcome updated
ACUTE NON ST ELEVATION MI 3/8/2021 NO SUBSTANCE USE DISORDER W DRUG WITHDRAWAL, UNSPECIFIED SYMPTOMS  HYPOXIA 3/2/2021 NO SUBSTANCE USE DISORDER W DRUG WITHDRAWAL, UNSPECIFIED SYMPTOMS  ACUTE NON ST ELEVATION MI 3/8/2021 ACUTE NON ST ELEVATION MI    CAD (CORONARY ARTERY DISEASE) WO ANGINA  HYPOXIA 3/2/2021 ACUTE NON ST ELEVATION MI    CAD (CORONARY ARTERY DISEASE) WO ANGINA  ACUTE NON ST ELEVATION MI 3/8/2021 OPIOID INDUCED CONSTIPATION, THERAPEUTIC USE, INIT  HYPOXIA 3/2/2021 OPIOID INDUCED CONSTIPATION, THERAPEUTIC USE, INIT  ACUTE NON ST ELEVATION MI 3/8/2021 CAD (CORONARY ARTERY DISEASE) WO ANGINA  HYPOXIA 3/2/2021 CAD (CORONARY ARTERY DISEASE) WO ANGINA
Vaccine was initially stored in refrigerator (lot number: as7173B) on 06-Mar-2023 and vaccine was administered on 12-Apr-2023; no adverse event; 10 patients received vaccine that was stored in the refrigerator past 30-day storage mark, from vaccine Lot number as7173B and 069H22a.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (10 patients received vaccine that was stored in the refrigerator past 30-day storage mark, from vaccine Lot number as7173B and 069H22a.), PRODUCT STORAGE ERROR (Vaccine was initially stored in refrigerator (lot number: as7173B) on 06-Mar-2023 and vaccine was administered on 12-Apr-2023) and NO ADVERSE EVENT (no adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. as7173B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 12-Apr-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 12-Apr-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (10 patients received vaccine that was stored in the refrigerator past 30-day storage mark, from vaccine Lot number as7173B and 069H22a.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was initially stored in refrigerator (lot number: as7173B) on 06-Mar-2023 and vaccine was administered on 12-Apr-2023) and NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (10 patients received vaccine that was stored in the refrigerator past 30-day storage mark, from vaccine Lot number as7173B and 069H22a.), PRODUCT STORAGE ERROR (Vaccine was initially stored in refrigerator (lot number: as7173B) on 06-Mar-2023 and vaccine was administered on 12-Apr-2023) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (10 patients received vaccine that was stored in the refrigerator past 30-day storage mark, from vaccine Lot number as7173B and 069H22a.) and PRODUCT STORAGE ERROR (Vaccine was initially stored in refrigerator (lot number: as7173B) on 06-Mar-2023 and vaccine was administered on 12-Apr-2023).    Concomitant product use was not provided by the reporter.  Treatment information was not provided.  This case contains information about patient 6th out of 10 adult patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-728204 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-728204: case
expired vaccine used; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (expired vaccine used) in a 72-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Nov-2021 at 11:04 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 04-Nov-2021 at 11:04 AM, the patient experienced EXPIRED PRODUCT ADMINISTERED (expired vaccine used). On 04-Nov-2021 at 11:04 AM, EXPIRED PRODUCT ADMINISTERED (expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Treatment information was not provided.
Herpes; shingles; rash that spread; small heart shaped redness on left shoulder; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of HERPES VIRUS INFECTION (Herpes) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HERPES VIRUS INFECTION (Herpes) (seriousness criterion medically significant), HERPES ZOSTER (shingles), RASH (rash that spread) and VACCINATION SITE ERYTHEMA (small heart shaped redness on left shoulder). At the time of the report, HERPES VIRUS INFECTION (Herpes), HERPES ZOSTER (shingles), RASH (rash that spread) and VACCINATION SITE ERYTHEMA (small heart shaped redness on left shoulder) outcome was unknown.            Concomitant product use was not provided by the reporter. Treatment information was not provided.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   This case was linked to MOD-2021-142373 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
This spontaneous report as received from a nurse refers to unspecified patients of unknown age and gender. Information regarding their medical history and concomitant medications was not provided. On an unknown dates from 15-DEC-2017 to 01-JAN-2018, the patients were vaccinated with improperly stored doses of ROTATEQ lot # N005617, expiration date 03-OCT-2018 (strength and dose were not provided), VAQTA lot # M038572, expiration date 11-MAR-2018 (strength, dose and route were not provided) and PNEUMOVAX 23 lot # N025656, expiration date 19-APR-2019 (strength, dose and route were not provided), all for prophylaxis. No adverse effects were reported. There was a data logger involved. Time frame and temperature excursion details were not provided. There was previous unspecified temperature excursion.
second dose administered on 05-DEC-2003; This spontaneous report was received from a physician via an immunization record from a case in litigation for quadrivalent human papillomavirus (types 6,11,16,18) recomb. Vaccine (GARDASIL) (2303USA000366), and concerns an approximately 5-month-old female patient. The patient's concurrent conditions, medical history and concomitant medications were not provided.  On 23-OCT-2003, the patient was vaccinated with the first dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) (lot #, expiry date, route of administration and anatomical location were not provided). On 05-DEC-2003, she was vaccinated with the second dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) (lot #, expiry date, route of administration and anatomical location were not provided), which was considered an inappropriate schedule of vaccine administered.   This is one of four reports regarding the same patient.; Sender's Comments:  US-009507513-2303USA000366: US-009507513-2305USA005506: US-009507513-2305USA005505:
Patient received vaccines listed on 3/30/17. After vaccine administration mother noticed small bump at the area. Was seen in clinic on 7/14/17 to assess the bump on right thigh and ultrasound was ordered and completed on 7/26/17. Patient returned to clinic for an additional appt on 9/12/17 due to area increasing in size. Since then the size of the area has increased and area spread according to mother's reports and patient was taken to ER recently. There she was given instructions to wrap, massage area and apply cold/heat.
Inflammation BELOW double injection site.  Initially, began as about 1/2 inch wide by 4 inches long.  Reached approximately 4 inches wide diagonally down and around my upper arm before beginning to recede.
This case was reported by a health care professional and described the occurrence of autism in a male subject of unspecified age who was vaccinated with diphtheria and tetanus toxoids and acellular pertussis vaccine absorbed for prophylaxis. The subject was 3 years old at the time of reporting. On 12/24/02, when the subject was two months old, he received the 1st dose of Infanrix (lot number 578B9). On 2/24/03, when the subject was four months old, he received the 2nd dose of Infanrix (lot number 583B2). On an unspecified date on or before 4/18/06, the subject developed autism. The outcome of the autism was unresolved. The vaccination series was completed with Tripedia. Comment: Autism was assessed as medically serious (OMIC).
Immediate erythema at site of injection on left thigh followed by macular rash in upper and lower extremities and cheeks. 9mg PO Benadryl given.
ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 11/26/2021 ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY  ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 11/26/2021 FEVER  ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 11/26/2021 LATE EFFECT OF STROKE  ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 11/26/2021 PALLIATIVE CARE
Portal Vein Thrombosis; abdominal pain; This is a spontaneous report from a contactable consumer (patient). A 49-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number EN6206 and expiration date not provided), via an unspecified route of administration, administered in Arm Left first dose on 18Mar2021 17:00 at single dose for covid-19 immunisation. The patient's medical history included obesity. There were no concomitant medications. About four days after vaccine on 22Mar2021, the patient stared having abdominal pain.  On 31Mar2021, the pain caused the patient to go to the ER and physician office visit, where the patient was diagnosed with a portal vein thrombosis. The patient was then hospitalized for 2 days. The patient was treated with Eliquis.  The outcome of the events was recovering.
Information has been received from a physician concerning a female who was vaccinated with a dose of ZOSTAVAX (Merck). On an unknown date, the patient developed a zoster like rash after vaccination with ZOSTAVAX (Merck). The patient sought medical attention in the office. The patient's outcome was unknown. Follow-up information has been received from the physician concerning a 65 year old female with hypothyroidism, hypertension, regular alcohol use, gastroesophageal reflux disease (GERD) and illness at the time of vaccination included urinary tract infection (UTI) who on 25-SEP-2007 was vaccinated subcutaneously with the first dose of ZOSTAVAX (Merck) (lot # 658208/0886U) in the left arm. On 04-AUG-2008 the patient was diagnosed with herpes zoster with postherpetic neuralgia (ongoing). At the time of reporting, the patient had not recovered. Herpes zoster and postherpetic neuralgia were considered to be disabling by the physician. Additional information is available.
Blurring of eyes; Flu like symptoms; Visual disturbance; This spontaneous case was reported by a consumer and describes the occurrence of VISUAL IMPAIRMENT (Visual disturbance), VISION BLURRED (Blurring of eyes) and INFLUENZA LIKE ILLNESS (Flu like symptoms) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027L20A and 012M20A) for COVID-19 vaccination.     The patient's past medical history included Head injury.   On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Feb-2021, the patient experienced VISUAL IMPAIRMENT (Visual disturbance). On an unknown date, the patient experienced VISION BLURRED (Blurring of eyes) and INFLUENZA LIKE ILLNESS (Flu like symptoms). At the time of the report, VISUAL IMPAIRMENT (Visual disturbance), VISION BLURRED (Blurring of eyes) and INFLUENZA LIKE ILLNESS (Flu like symptoms) outcome was unknown.            .   Most recent FOLLOW-UP information incorporated above includes: On 29-Apr-2021: Added HCP details, patient demographic details, vaccine information, events
Patient developed a fine, red rash over torso and legs with itching reported on8/22/2006.
Suspected pericarditis; flu shot at 3pm and feeling fine until 2 am that night about waking up with chest tightness and feeling wide awake; as the day progressed tightness worsened and became painful; pain with deep breathing; pain with lieing down in the center of chest or when bending over; went to urgent care around 4pm and they sent me to ED given my symptoms; was in ED until about 9pm and was diagnosised with pericarditis and to take nsaids
Pt. states that after receiving the 1st dose of Moderna 10/18/2021, started experiencing symptoms 11/01/2021 of hair loss to the right side of the head. Hair is coming out in "chunks". No noted Primary visit/communications.
Patient has been called about the Bivalent shot and will get that one in 2 months.
About 5-6 hours after injection, I experienced soreness in arm; About 5-6 hours after injection, general fatigue; About 12 hours later, I have a mild headache; About 12 hours later, Mild fever; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (About 5-6 hours after injection, I experienced soreness in arm), FATIGUE (About 5-6 hours after injection, general fatigue), HEADACHE (About 12 hours later, I have a mild headache) and PYREXIA (About 12 hours later, Mild fever) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007G21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 50 mcg. In December 2021, the patient experienced PAIN IN EXTREMITY (About 5-6 hours after injection, I experienced soreness in arm) and FATIGUE (About 5-6 hours after injection, general fatigue). December 2021, the patient experienced HEADACHE (About 12 hours later, I have a mild headache) and PYREXIA (About 12 hours later, Mild fever). At the time of the report, PAIN IN EXTREMITY (About 5-6 hours after injection, I experienced soreness in arm), FATIGUE (About 5-6 hours after injection, general fatigue), HEADACHE (About 12 hours later, I have a mild headache) and PYREXIA (About 12 hours later, Mild fever) outcome was unknown.            Concomitant medication of the patient was not reported.  No treatment information was provided by the reporter.
Generalized rash on 4/23/06, fever to 101 on 4/23/06. On 4/22/06 achiness in B knees and R parotid tenderness on 4/23/06. Appears to be resolving. Rash and arthralgias still present.
After having the vaccination I experienced chronic diarrhea that has not subsided. I scheduled an appointment with my physician to discuss symptoms.
after 2 weeks of receiving the chicken pox vaccine, the pt developed a mild case of the chickenpox.
Have had regular periods for years but after the first dose of Covid vaccine I still haven?t gotten my period and it had been months. I am not pregnant.
Febrile seizure, lasted 2-3 minutes. Seen at ER. Tmax 105.3.
Relieved by taking OTC ADVIL and sleeping. Headache, Fever and Flu-like symptoms. Ibuprofen.
Information has been received from a health professional concerning a 43 year old female with no known allergies or medical history who on 12-JUN-2006 was vaccinated with MMR. On 01-Mar-2007, the patient had a titer drawn that showed that she failed to seroconvert to measles only. The health professional reported that the patient will probably get revaccinated with the MMR. Medical attention was sought. Additional information has been requested.
Bruised and sore, symptoms started clearing up 10/7/13, as reported by husband 10/8/13.